Body Mass Index Quantitative Trait Locus 7 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

BMIQ7 MCID: BDY012 MIFTS: 43	Body Mass Index Quantitative Trait Locus 7 (BMIQ7) Categories: Bone diseases, Endocrine diseases, Genetic diseases, Metabolic diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Body Mass Index Quantitative Trait Locus 7

MalaCards integrated aliases for Body Mass Index Quantitative Trait Locus 7:

Name: Body Mass Index Quantitative Trait Locus 7 ⁵⁷ ¹²

Obesity ⁵⁷ ⁷¹

Obesity, Susceptibility to, Bmiq7 ⁵⁷

Obesity, Susceptibility to ⁵⁷

Obesity Bmiq7 ⁵⁷

Bmiq7 ⁵⁷

Classifications:

MalaCards categories:
Global: Metabolic diseases Genetic diseases
Anatomical: Endocrine diseases Bone diseases

See all MalaCards categories (disease lists)

External Ids:

OMIM® ⁵⁷ 608410

UMLS ⁷¹ C0028754

Sources

Summaries for Body Mass Index Quantitative Trait Locus 7

MalaCards based summary: Body Mass Index Quantitative Trait Locus 7, also known as obesity, is related to body mass index quantitative trait locus 11 and leptin deficiency or dysfunction, and has symptoms including symptoms, high weight and obesity, metabolically benign. An important gene associated with Body Mass Index Quantitative Trait Locus 7 is BMIQ7 (Obesity, Susceptibility To, On Chromosome 4). The drugs Vildagliptin and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, liver and brain.

More information from OMIM: 608410

Sources

Related Diseases for Body Mass Index Quantitative Trait Locus 7

Diseases in the Body Mass Index Quantitative Trait Locus 11 family:

Body Mass Index Quantitative Trait Locus 9	Body Mass Index Quantitative Trait Locus 8
Body Mass Index Quantitative Trait Locus 1	Body Mass Index Quantitative Trait Locus 2
Body Mass Index Quantitative Trait Locus 3	Body Mass Index Quantitative Trait Locus 4
Body Mass Index Quantitative Trait Locus 10	Body Mass Index Quantitative Trait Locus 7
Body Mass Index Quantitative Trait Locus 5	Body Mass Index Quantitative Trait Locus 6
Body Mass Index Quantitative Trait Locus 12	Body Mass Index Quantitative Trait Locus 13
Body Mass Index Quantitative Trait Locus 14	Body Mass Index Quantitative Trait Locus 15
Body Mass Index Quantitative Trait Locus 18	Body Mass Index Quantitative Trait Locus 19
Body Mass Index Quantitative Trait Locus 20

Diseases related to Body Mass Index Quantitative Trait Locus 7 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2456)

#	Related Disease	Score
1	body mass index quantitative trait locus 11	12.1
2	leptin deficiency or dysfunction	11.9
3	body mass index quantitative trait locus 19	11.9
4	body mass index quantitative trait locus 20	11.9
5	body mass index quantitative trait locus 8	11.9
6	body mass index quantitative trait locus 12	11.9
7	body mass index quantitative trait locus 14	11.9
8	body mass index quantitative trait locus 4	11.9
9	body mass index quantitative trait locus 9	11.8
10	body mass index quantitative trait locus 18	11.8
11	body mass index quantitative trait locus 10	11.8
12	leptin receptor deficiency	11.8
13	abdominal obesity-metabolic syndrome 1	11.6
14	obesity, early-onset, with adrenal insufficiency and red hair	11.6
15	obesity-hypoventilation syndrome	11.6
16	intellectual developmental disorder, x-linked, syndromic, wilson-turner type	11.5
17	cohen syndrome	11.5
18	abdominal obesity-metabolic syndrome 3	11.5
19	mehmo syndrome	11.5
20	proprotein convertase 1/3 deficiency	11.5
21	abdominal obesity-metabolic syndrome 4	11.5
22	mental retardation, truncal obesity, retinal dystrophy, and micropenis syndrome	11.5
23	morbid obesity and spermatogenic failure	11.5
24	abdominal obesity-metabolic syndrome quantitative trait locus 2	11.4
25	momo syndrome	11.4
26	type 2 diabetes mellitus	11.4
27	chops syndrome	11.4
28	spastic paraplegia, intellectual disability, nystagmus, and obesity	11.4
29	coenzyme q10 deficiency, primary, 2	11.4
30	chung-jansen syndrome	11.4
31	obesity, hyperphagia, and developmental delay	11.4
32	retinal dystrophy and obesity	11.3
33	non-alcoholic fatty liver disease	11.3
34	hypothalamic obesity	11.3
35	fatty liver disease	11.3
36	hydrocephalus obesity hypogonadism	11.3
37	obesity due to sim1 deficiency	11.3
38	coloboma-obesity-hypogenitalism-mental retardation syndrome	11.3
39	aniridia - ptosis - intellectual disability - familial obesity	11.3
40	rohhad	11.3
41	rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome	11.3
42	prader-willi syndrome	11.3
43	prediabetes syndrome	11.3
44	severe early-onset obesity-insulin resistance syndrome due to sh2b1 deficiency	11.3
45	camera-marugo-cohen syndrome	11.2
46	wilms tumor, aniridia, genitourinary anomalies, mental retardation, and obesity syndrome	11.2
47	mental retardation, obesity, mandibular prognathism, and eye and skin anomalies	11.2
48	ayazi syndrome	11.2
49	glucose intolerance	11.2
50	short stature, brachydactyly, impaired intellectual development, and seizures	11.2

Graphical network of the top 20 diseases related to Body Mass Index Quantitative Trait Locus 7:

Sources

Symptoms & Phenotypes for Body Mass Index Quantitative Trait Locus 7

Clinical features from OMIM®:

608410 (Updated 08-Dec-2022)

UMLS symptoms related to Body Mass Index Quantitative Trait Locus 7:

symptoms; high weight; obesity, metabolically benign; monogenic obesity

Sources

Drugs & Therapeutics for Body Mass Index Quantitative Trait Locus 7

Drugs for Body Mass Index Quantitative Trait Locus 7 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 934)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Vildagliptin

Approved, Investigational

Phase 4

274901-16-5

6918537

Lactitol

Approved, Investigational

Phase 4

585-86-4

157355

Dexlansoprazole

Approved, Investigational

Phase 4

138530-94-6

9578005

Lansoprazole

Approved, Investigational

Phase 4

103577-45-3

3883

Indapamide

Approved

Phase 4

26807-65-8

3702

Insulin lispro

Approved

Phase 4

133107-64-9

16132438

Erythromycin

Approved, Investigational, Vet_approved

Phase 4

114-07-8

12560

Insulin aspart

Approved

Phase 4

116094-23-6

16132418

Hydroxychloroquine

Approved

Phase 4

118-42-3

3652

Metyrapone

Approved, Investigational

Phase 4

54-36-4

4174

Cyproterone acetate

Approved, Investigational

Phase 4

427-51-0

9880

Tolnaftate

Approved, Investigational, Vet_approved

Phase 4

2398-96-1

5510

Phentermine

Approved, Illicit

Phase 4

122-09-8

4771

Rosiglitazone

Approved, Investigational

Phase 4

122320-73-4, 155141-29-0

77999

Coal tar

Approved

Phase 4

8007-45-2

Loperamide

Approved

Phase 4

53179-11-6

3955

Heparin, bovine

Approved, Investigational, Withdrawn

Phase 4

9005-49-6

22833565 9812414 772

Rocuronium

Approved

Phase 4

119302-91-9, 143558-00-3

441290

Levoleucovorin

Approved, Experimental, Investigational

Phase 4

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Calcium carbonate

Approved, Investigational

Phase 4

471-34-1

Ursodeoxycholic acid

Approved, Investigational

Phase 4

128-13-2

31401

Tomato

Approved

Phase 4

Dapagliflozin

Approved

Phase 4

461432-26-8

9887712

Infliximab

Approved

Phase 4

170277-31-3

Octreotide

Approved, Investigational

Phase 4

83150-76-9

383414 6400441

Saxagliptin

Approved

Phase 4

361442-04-8

11243969

Ethinylestradiol

Approved

Phase 4

57-63-6

5991

Norgestimate

Approved, Investigational

Phase 4

35189-28-7

6540478

Moxifloxacin

Approved, Investigational

Phase 4

186826-86-8, 354812-41-2, 151096-09-2

152946

Desflurane

Approved

Phase 4

57041-67-5

42113

Zonisamide

Approved, Investigational

Phase 4

68291-97-4

5734

Apixaban

Approved

Phase 4

503612-47-3

10182969

Parathyroid hormone

Approved, Investigational

Phase 4

9002-64-6

Orange

Approved

Phase 4

Drospirenone

Approved

Phase 4

67392-87-4

68873

Glyburide

Approved

Phase 4

10238-21-8

3488

Atorvastatin

Approved

Phase 4

134523-00-5

60823

Risedronic acid

Approved, Investigational

Phase 4

105462-24-6

5245

Memantine

Approved, Investigational

Phase 4

41100-52-1, 19982-08-2

4054

Cyclophosphamide

Approved, Investigational

Phase 4

50-18-0, 6055-19-2

2907

Letrozole

Approved, Investigational

Phase 4

112809-51-5

3902

Galantamine

Approved

Phase 4

357-70-0, 1953-04-4

9651

Amoxicillin

Approved, Vet_approved

Phase 4

26787-78-0

33613

Anidulafungin

Approved, Investigational

Phase 4

166663-25-8

166548

Chenodeoxycholic acid

Approved

Phase 4

474-25-9

10133

Bismuth subsalicylate

Approved, Vet_approved

Phase 4

14882-18-9

53629521 16682734

Clarithromycin

Approved

Phase 4

81103-11-9

84029

Ropivacaine

Approved

Phase 4

84057-95-4

71273 175805

Nadroparin

Approved, Investigational

Phase 4

Neostigmine

Approved, Vet_approved

Phase 4

59-99-4

4456 5824

Interventional clinical trials:

(show top 50) (show all 8963)

#	Name	Status	NCT ID	Phase	Drugs
1	Evaluation of the Effects of Laying Early (Between 12 and 16) a Gastric Band on the Prevention of Morbid Obesity in Late Adolescence. Randomized Checked Against Standard Management of Obesity in This Population.	Unknown status	NCT01700738	Phase 4
2	Prevention and Control of Obesity in Primary School Children in Tehran	Unknown status	NCT02082080	Phase 4
3	A Study of the Pharmacokinetics of Dexmedetomidine in Morbid Obesity.	Unknown status	NCT01864187	Phase 4	Dexmedetomidine
4	The Effect of Moxonidine and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension: a Randomised, Double Blind, Active Comparator Clinical Trial	Unknown status	NCT01360710	Phase 4	Moxonidine;Irbesartan
5	Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study	Unknown status	NCT02999841	Phase 4	Acarbose;Vildagliptin
6	Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity	Unknown status	NCT01960205	Phase 4	Saxagliptin;saxagliptin;metformin
7	The Therapeutic Effect of Catgut Embedding in Obesity-A Randomized, Double-blind, Placebo-controlled Clinical Trial	Unknown status	NCT02276235	Phase 4
8	Trial Evaluating Effectiveness of Contrave (Naltrexone HCl / Bupropion HCl) for Weight Maintenance in Adults With BMI ≥ 27 Kg/m2, After 6 Month Intensive Behavior Modification Program: Contrave Obesity Trials (COR) Weight Maintenance Study	Unknown status	NCT04589130	Phase 4	Contrave 8Mg-90Mg Extended-Release Tablet;Placebo
9	Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B	Unknown status	NCT02759393	Phase 4	Dexlansoprazole;Lansoprazole
10	The Effect of Obesity in Dexmedetomidine Metabolic Clearance	Unknown status	NCT02557867	Phase 4	Dexmedetomidine
11	Treatment of Obesity With Topiramate in Patients With Polycystic Ovary Syndrome: a Double-blind Placebo-controlled Clinical Trial	Unknown status	NCT04453306	Phase 4	Topiramate;Placebo
12	Effect and Safety of Benaglutide or Metformin in Patients With Simple Obesity Who Have Inadequate Weight Control :A Randomized, Open, Controlled and Single-site Clinical Trail	Unknown status	NCT03593668	Phase 4	Metformin;Benaglutide
13	Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity	Unknown status	NCT02438020	Phase 4	Metformin
14	Assessment of the Effect of Moxonidine and Diet on Cardiac, Renal and Endothelial Function in Young Subjects With Abdominal Obesity	Unknown status	NCT01180231	Phase 4	Moxonidine (Physiotens)
15	Correlation of Postoperative VAS Values and Body Mass Index in Patients Undergoing Abdominal Surgery: A Clinical Trial	Unknown status	NCT02017314	Phase 4	Morphine
16	Prospective Randomized Study of Effects of Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy	Unknown status	NCT00667706	Phase 4
17	Laparoscopic Non Banded Vertical (Magenstrasse and Mill) Gastroplasty In Bariatric Surgery. Morbidity and Results on Weight Loss and Associated Co-morbidities	Unknown status	NCT02050477	Phase 4
18	Comparing the Efficacy of Two Frequently Used Doses of Enoxaparin for VTE Prophylaxis After Bariatric Surgery	Unknown status	NCT01970202	Phase 4	40mg Enoxaparin;60mg Enoxaparin
19	Effect of Docosahexaenoic Acid Supplementation on Microbiome in Obese ChiLdrEn. The DAMOCLE Study	Unknown status	NCT04151758	Phase 4	Docosahexaenoic Acid Supplementation
20	Laparoscopic Bariatric Surgery: Impact of the Level of Neuromuscular Blockade on Surgical Conditions - Comparison Between Moderate and Deep Neuromuscular Blockade	Unknown status	NCT02118844	Phase 4	rocuronium
21	Preoperative Carbohydrate Loading in Bariatric Surgery - Randomized Clinical Trail	Unknown status	NCT04486079	Phase 4
22	Effect of POSTbiotics Supplementation on Microbiome in OBese Children: the POST-OB Study	Unknown status	NCT04151823	Phase 4	Vitamin D3;Immunofos
23	Prospective, Pharmacokinetic Study for Determination of the Relationship Between Lean Body Weight and Anti-Xa Activity 4 Hours After Subcutaneous Injection of 5700 IU Nadroparin in Morbidly Obese Patients After Bariatric Surgery.	Unknown status	NCT02295150	Phase 4	Nadroparin
24	Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass	Unknown status	NCT02374632	Phase 4
25	Could Gut Microbiome Contribute to the Therapeutic Effect of Liraglutide 3.0 mg? A Randomized Double Blind Placebo Controlled Trial	Unknown status	NCT04046822	Phase 4	Liraglutide 6 MG/ML [Saxenda];Placebo
26	Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project	Unknown status	NCT01015599	Phase 4
27	Laparoscopic Roux-en-Y Gastric Bypass vs. Laparoscopic BPD-Duodenal Switch for Superobesity (BMI > 50 kg/m2)- A Randomized Clinical Trial	Unknown status	NCT00327912	Phase 4
28	International, Multi Centre, Open, Prospective, Randomized Study: Banded Versus Conventional Laparoscopic Roux-en-Y (GABY)	Unknown status	NCT01015469	Phase 4
29	The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals	Unknown status	NCT01405352	Phase 4
30	Levonorgestrel-releasing Intrauterine Device Effects on Hemostatic and Arterial Function of Obese Women	Unknown status	NCT01320917	Phase 4
31	Endobarrier Treatment in Obese Subjects With T2DM	Unknown status	NCT01718457	Phase 4
32	Structured Exerise Training in Infertile Obese Patients Treated With Assisted Reproductive Techniques: a Randomized Controlled Trial	Unknown status	NCT01892111	Phase 4
33	Efficacy and Safety of Liraglutide-bolus (Liraglutide Plus Prandial Insulin) Versus Glargine-bolus Therapy in Overweight / Obese Patients With Uncontrolled Type 2 Diabetes (LiraGooD)--A Multicenter Randomized Controlled Study	Unknown status	NCT03087032	Phase 4	Liraglutide;insulin glargine
34	Effects of Valsartan on Metabolic Syndrome in Patients With Hypertension	Unknown status	NCT00790946	Phase 4	Valsartan
35	Evaluation of Family Intervention Program for the Treatment of Overweight or Obese Children (Nereu Program): Randomized Clinical Trial	Unknown status	NCT01878994	Phase 4
36	Influence of Erythromycin on ad Libitum Food Intake and the Evaluation of Motilin in Food Timing in Healthy Volunteers and Patients	Unknown status	NCT03024879	Phase 4	Erythromycin;Saline
37	Study of Metabolic Effects of EndoBarrier Versus Intragastric Balloon in Obese Patients With Type 2 Diabetes.	Unknown status	NCT01848795	Phase 4
38	Beijing Chao-yang Hospital, Capital Medical University	Unknown status	NCT02583438	Phase 4	Saxagliptin (Bristol-Myers Squibb Company)
39	A 24-Week, National, Single-Centre, Open-Labelled, Randomised, Parallel-Group Trial Comparing Energy Expenditure With Insulin Detemir Versus NPH Insulin Using a Basal-Bolus Regimen With Insulin Aspart as the Mealtime Insulin in Subjects With Type 2 Diabetes	Unknown status	NCT00788840	Phase 4	Insulatard;Detemir
40	Randomisation to Endoluminal Intestinal Liner Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)	Unknown status	NCT02055014	Phase 4	Liraglutide
41	Synergy Effect of the Appetite Hormone GLP-1 (LiragluTide) and Exercise on Maintenance of Weight Loss and Health After a Low Calorie Diet - the S-LiTE Randomized Trial	Unknown status	NCT04122716	Phase 4	Liraglutide
42	The Efficacy of a Once Weekly Glucagon-Like Peptide-1 Agonist on Body Weight/Composition and Metabolic Parameters in Persons With SCI	Unknown status	NCT03292315	Phase 4	Exenatide 2 MG Injection [Bydureon]
43	The Effect of Mirabegron on Brown Adipose Tissue in Healthy Young White Caucasian and South Asian Men	Unknown status	NCT03012113	Phase 4	Mirabegron;Placebo Oral Capsule
44	The Effect of Exenatide on Brown Adipose Tissue Activity and Energy Expenditure in Healthy Young Men	Unknown status	NCT03002675	Phase 4	Bydureon
45	Sildenafil Activates Browning of White Adipose and Improves Insulin Sensitivity in Human Adults	Unknown status	NCT02524184	Phase 4	sildenafil;placebo
46	The Effect of Hydroxychloroquine Sulphate on Hedonic Food Intake, Appetite-related Sensations and Gastrointestinal Hormone Release in Overweight Female Subjects	Unknown status	NCT04005781	Phase 4	Hydroxychloroquine sulphate;Placebo
47	The Effect of Hydroxychloroquine Sulphate on Hedonic Food Intake, Appetite-related Sensations and Gastrointestinal Hormone Release in Healthy Female Subjects	Unknown status	NCT04005768	Phase 4	Hydroxychloroquine Sulphate;Placebo
48	Metformin Treatment for Preventing Gestational Diabetes in High-risk Patients	Unknown status	NCT00883259	Phase 4	Metformin
49	The Effects of Cortisol Blockade on Nutritional Sympathetic Nervous System Responsiveness in Overweight and Obese Subjects With Metabolic Syndrome	Unknown status	NCT01620684	Phase 4	metyrapone;placebo
50	A Pilot Study: Comparing Physiological Parameters and Outcome Variables Using Pressure Support Ventilation Versus Pressure Controlled Ventilation in Patients With Chronic Respiratory Failure	Unknown status	NCT00994552	Phase 4

Search NIH Clinical Center for Body Mass Index Quantitative Trait Locus 7

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Benzphetamine

Benzphetamine hydrochloride

Dexfenfluramine

Dexfenfluramine Hydrochloride

Diethylpropion

Diethylpropion Hydrochloride

Fenfluramine

Fenfluramine Hydrochloride

lorcaserin

lorcaserin hydrochloride

Mazindol

Methamphetamine

orlistat

phendimetrazine

PHENDIMETRAZINE HYDROCHLORIDE

phendimetrazine tartrate

Phenmetrazine

Phenmetrazine Hydrochloride

Phentermine

Phentermine Hydrochloride

PHENTERMINE RESIN

Phenylpropanolamine

Phenylpropanolamine Hydrochloride

sibutramine

SIBUTRAMINE HYDROCHLORIDE

Sources

Genetic Tests for Body Mass Index Quantitative Trait Locus 7

Sources

Anatomical Context for Body Mass Index Quantitative Trait Locus 7

Organs/tissues related to Body Mass Index Quantitative Trait Locus 7:

MalaCards : Skeletal Muscle, Liver, Brain, Adipocyte, Heart, Breast, Endothelial

Sources

Publications for Body Mass Index Quantitative Trait Locus 7

Articles related to Body Mass Index Quantitative Trait Locus 7:

(show top 50) (show all 30003)

#	Title	Authors	PMID	Year
1	R125W coding variant in TBC1D1 confers risk for familial obesity and contributes to linkage on chromosome 4p14 in the French population. ⁶² ⁵⁷	Meyre D...Froguel P	18325908	2008
2	TBC1D1 is a candidate for a severe obesity gene and evidence for a gene/gene interaction in obesity predisposition. ⁶² ⁵⁷	Stone S...Shattuck D	16893906	2006
3	Evidence of a novel quantitative-trait locus for obesity on chromosome 4p in Mexican Americans. ⁶² ⁵⁷	Arya R...Stern MP	14740316	2004
4	A major predisposition locus for severe obesity, at 4p15-p14. ⁶² ⁵⁷	Stone S...Shattuck D	11957135	2002
5	Addiction-like behaviour towards high-fat high-sugar food predicts relapse propensity in both obesity prone and obesity resistant C57BL/6 J mice. ⁶²	Horton AL...Brown RM	36209772	2023
6	Ultra-processed food consumption and adult obesity risk: a systematic review and dose-response meta-analysis. ⁶²	Moradi S...Miraghajani M	34190668	2023
7	Impact of Age on Obesity-related Comorbidity After Gastric Bypass: A Cohort Study From the Scandinavian Obesity Surgery Registry (SOReg). ⁶²	Gerber P...Thorell A	33856387	2022
8	Obstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity Society. ⁶²	Friedman AN...Kaplan LM	36280397	2022
9	Obstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society. ⁶²	Friedman AN...Kaplan LM	36268562	2022
10	Gut Microbiome and Its Impact on Obesity and Obesity-Related Disorders. ⁶²	Sankararaman S...Martindale R	36469257	2022
11	Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. ⁶²	Lopez-Jimenez F...Wilding JPH	36007112	2022
12	Relationship Between Moderate-to-Vigorous Physical Activity and Glycemia Among Young Adults with Type 1 Diabetes and Overweight or Obesity: Results from the Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) Study. ⁶²	Muntis FR...ACT1ON Consortium	35984327	2022
13	The impact of obesity on the outcome of severe SARS-CoV-2 ARDS in a high volume ECMO centre: ECMO and corticosteroids support the obesity paradox. ⁶²	Balik M...Blaha J	36219946	2022
14	Impairment of gut microbial biotin metabolism and host biotin status in severe obesity: effect of biotin and prebiotic supplementation on improved metabolism. ⁶²	Belda E...Clement K	35017197	2022
15	Nutritional management of individuals with obesity and COVID-19: ESPEN expert statements and practical guidance. ⁶²	Barazzoni R...endorsed by the ESPEN Council	34140163	2022
16	Obesity and dietary fat influence dopamine neurotransmission: exploring the convergence of metabolic state, physiological stress, and inflammation on dopaminergic control of food intake. ⁶²	Wallace CW...Fordahl SC	34184629	2022
17	Genotype frequencies and the Hardy-Weinberg equilibrium on rs9939609 FTO and rs17782313 MC4R: Implications for statistical associations to overweight and obesity in children and adolescents (re. "Polymorphisms on rs9939609 FTO and rs17782313 MC4R genes in children and adolescent obesity: a systematic review"). ⁶²	Flores SV...Silva-Gonzalez O	35835628	2022
18	Secreted EMC10 is upregulated in human obesity and its neutralizing antibody prevents diet-induced obesity in mice. ⁶²	Wang X...Liew CW	36443308	2022
19	Targeted dietary approaches for the management of obesity and severe obesity in children and adolescents: A systematic review and meta-analysis. ⁶²	Southcombe F...Denney-Wilson E	36394356	2022
20	Improving applicability of the new obesity classification based on weight history in severe obesity. ⁶²	Candido FG...Hermsdorff HHM	36394489	2022
21	European Association for the Study of Obesity (EASO) position statement on medical nutrition therapy for the management of overweight and obesity in children and adolescents developed in collaboration with the European Federation of the Associations of Dietitians (EFAD). ⁶²	Hassapidou M...Collins C	36349767	2022
22	Reliable Knowledge about Obesity Risk, Rather Than Personality, Is Associated with Positive Beliefs towards Obese People: Investigating Attitudes and Beliefs about Obesity, and Validating the Polish Versions of ATOP, BAOP and ORK-10 Scales. ⁶²	Styk W...Zmorzynski S	36429694	2022
23	A Rapid Review of the Impact of Family-Based Digital Interventions for Obesity Prevention and Treatment on Obesity-Related Outcomes in Primary School-Aged Children. ⁶²	Chai LK...Littlewood R	36432522	2022
24	Re-evaluating obesity in Mexico-lessons for the global obesity epidemic. ⁶²	Jolin JR...Stanford FC	36442500	2022
25	Deciphering the "obesity paradox" in the elderly: A systematic review and meta-analysis of sarcopenic obesity. ⁶²	Liu C...Wong RMY	36443946	2022
26	Bifidobacterium bifidum DS0908 and Bifidobacterium longum DS0950 CultureSupernatants Ameliorate Obesity-Related Characteristics in Mice with High-Fat DietInduced Obesity. ⁶²	Rahman MS...Kim YS	36457182	2022
27	Differential regulation of nucleus accumbens glutamate and GABA in obesity-prone and obesity-resistant rats. ⁶²	Vollbrecht PJ...Ferrario CR	36336816	2022
28	Famine exposure in adolescence is associated with a higher risk of overweight/obesity and abdominal obesity in adulthood: A meta-analysis. ⁶²	Song Q...Sun Y	36215886	2022
29	The obesity paradox: Retinopathy, obesity, and circulating risk markers in youth with type 2 diabetes in the TODAY Study. ⁶²	Levitsky LL...TODAY Study Group	36150365	2022
30	Association of environmental exposure to perchlorate, nitrate, and thiocyanate with overweight/obesity and central obesity among children and adolescents in the United States of America using data from the National Health and Nutrition Examination Survey (NHANES) 2005-2016. ⁶²	Jiang Q...Li Q	36251327	2022
31	Gender-specific factors contributing to visceral obesity including the sleep-obesity relationship: a large-scale cross-sectional study from East Asia. ⁶²	Saito K...Yamamichi N	36434061	2022
32	Support needs of people living with obesity during transition from tertiary obesity treatment to community care. ⁶²	Alsultany G...McBride K	36207249	2022
33	The HIF1α polymorphism rs2301104 is associated with obesity and obesity-related cytokines in Han Chinese population. ⁶²	Zheng X...Ren W	36422747	2022
34	Antioxidant, Anti-Obesity, and Hypolipidemic Effects of Polyphenol Rich Star Anise (Illicium verum) Tea in High-Fat-Sugar Diet-Induced Obesity Rat Model. ⁶²	Iftikhar N...Abdullah Alnasser SM	36421427	2022
35	Sex differences in the association of physical activity levels and vitamin D with obesity, sarcopenia, and sarcopenic obesity: a cross-sectional study. ⁶²	Jia S...Dong B	36434519	2022
36	The founding of Obesity Research/Obesity: A brief history. ⁶²	Bray G	36321280	2022
37	The use of virtual visits for obesity pharmacotherapy in patients with overweight or obesity compared with in-person encounters. ⁶²	Griebeler ML...Burguera B	36156456	2022
38	Sarcopaenia, obesity, sarcopaenic obesity and outcomes following hepatic resection for colorectal liver metastases: a systematic review and meta-analysis. ⁶²	O'Connell RM...O'Sullivan AW	35922276	2022
39	Changes in obesity and iron deficiency between 4 and 9 years of age. Longitudinal study of childhood obesity (ELOIN). ⁶²	Cabanas Pujadas G...Galan I	35931811	2022
40	Fatty Liver/Adipose Tissue Dual-Targeting Nanoparticles with Heme Oxygenase-1 Inducer for Amelioration of Obesity, Obesity-Induced Type 2 Diabetes, and Steatohepatitis. ⁶²	Hong J...Kim YH	36209391	2022
41	Assessment of Overweight, Obesity, Central Obesity, and Type 2 Diabetes among Adolescents in Qatar: A Cross-Sectional Study. ⁶²	Cheema S...Mamtani R	36361482	2022
42	A hint for the obesity paradox and the link between obesity, perirenal adipose tissue and Renal Cell Carcinoma progression. ⁶²	Preza-Fernandes J...Ribeiro R	36402906	2022
43	The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits. ⁶²	Hinney A...Fischer-Posovszky P	35902734	2022
44	Butyrate to combat obesity and obesity-associated metabolic disorders: Current status and future implications for therapeutic use. ⁶²	van Deuren T...Canfora EE	35856338	2022
45	Microbiota modulation and anti-obesity effects of fermented Pyrus ussuriensis Maxim extract against high-fat diet-induced obesity in rats. ⁶²	Boby N...Park SC	36058150	2022
46	Sarcopenic Obesity Is Associated With Reduced Cardiorespiratory Fitness Compared With Nonsarcopenic Obesity in Patients With Heart Failure With Reduced Ejection Fraction. ⁶²	Billingsley HE...Carbone S	36098058	2022
47	Possible mediators of metabolic endotoxemia in women with obesity and women with obesity-diabetes in The Gambia. ⁶²	Jobe M...Prentice AM	35933445	2022
48	Intentional weight loss reduces cancer risk and mortality: New studies suggest that bariatric surgery can make a difference in risk and mortality reduction for obesity-related cancer types: New studies suggest that bariatric surgery can make a difference in risk and mortality reduction for obesity-related cancer types. ⁶²	Nierengarten MB	36161430	2022
49	Several areas of overlap between obesity and aging indicate obesity as a biomarker of accelerated aging of human B cell function and antibody responses. ⁶²	Frasca D	36289515	2022
50	HPA Axis Responsiveness Associates with Central Serotonin Transporter Availability in Human Obesity and Non-Obesity Controls. ⁶²	Schinke C...Hesse S	36358358	2022